Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genomics

Background:

• Epidermal growth factor receptor (EGFR) mutations are common in cancer, with varying mutation spectra across tumor types.
• While considered activating, the functional impact of specific EGFR mutations may differ, potentially explaining tumor-type specificity.

Purpose of the Study:

• To investigate functional differences between specific EGFR mutations (EGFR, EGFRvIII, EGFR-L858R).
• To determine if these mutations differ in binding partners, downstream pathway activation, and cellular effects on growth and migration.

Main Methods:

• Biotin pulldown followed by mass spectrometry to identify EGFR binding partners.
• Proximity ligation assay and Western Blot to confirm differential binding of DOCK4, UGGT1, MYCBP2, and SMTN.
• Gene expression analysis, phosphoprotein profiling, and stably expressing cell lines to assess functional consequences.

Main Results:

• Mutation-specific binding partners for EGFR were identified, including DOCK4, UGGT1, MYCBP2, and SMTN.
• Each EGFR mutation induced a unique set of gene expression changes and distinct phosphorylation patterns.
• EGFRvIII and EGFR-L858R mutations resulted in reduced cellular growth and migration compared to wild-type EGFR.

Conclusions:

• Distinct functional differences exist between various EGFR mutations.
• These functional disparities suggest the need for developing mutation-specific targeted therapies for cancer treatment.